Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP)
- 1 October 1986
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 22 (10), 1193-1197
- https://doi.org/10.1016/0277-5379(86)90320-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- High-dose cytosine arabinoside in multiple myelomaEuropean Journal of Cancer and Clinical Oncology, 1984
- Cross-resistance to alkylating agents in multiple myelomaCancer, 1983
- Progress report on vindesine treatment of melphalan-resistant multiple myelomaEuropean Journal of Cancer and Clinical Oncology, 1983
- Vindesine therapy in melphalan-resistant multiple myelomaEuropean Journal of Cancer (1965), 1981
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myelomaCancer, 1978
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolAmerican Journal Of Medicine, 1977
- Combination therapy for multiple myelomaCancer, 1977
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataBiometrics, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958